Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis

被引：0

作者：

Kim, Tae Min ^{[1
,2
]}

Guarneri, Valentina ^{[3
]}

Voon, Pei Jye ^{[4
]}

Lim, Boon Khaw ^{[5
]}

Yang, Jin-ji ^{[6
,7
]}

Wislez, Marie ^{[8
]}

Huang, Cheng ^{[9
]}

Liam, Chong Kin ^{[10
]}

Mazieres, Julien ^{[11
]}

Tho, Ye Mun ^{[12
]}

Hayashi, Hidetoshi ^{[13
]}

Nhung Nguyen ^{[14
]}

Chia, Puey Ling ^{[15
]}

de Marinis, Filippo ^{[16
]}

Raskin, Jo ^{[17
]}

Zhou, Qinghua ^{[18
]}

Finocchiaro, Giovanna ^{[19
]}

Le, Xiuning ^{[20
]}

Tan, Daniel ^{[21
]}

O'Hara, Richard M., Jr. ^{[22
]}

Brutlach, Sabine ^{[23
]}

O'Brate, Aurora ^{[24
]}

Adrian, Svenja ^{[25
]}

Berghoff, Karin ^{[26
]}

Ellers-Lenz, Barbara ^{[27
]}

Karachaliou, Niki ^{[25
]}

Wu, Yi-Long ^{[7
,28
]}

机构：

[1] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea

[2] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[3] Univ Padua, IOV Ist Oncol Veneto IRCCS IOV, Dept Surg Oncol & Gastroenterol, Oncol 2, Padua, Italy

[4] Hosp Umum Sarawak, Sarawak, Malaysia

[5] Sunway Med Ctr, Dept Internal & Resp Med, Subang Jaya, Selangor, Malaysia

[6] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Dept Oncol, Guangzhou, Peoples R China

[7] Guangdong Acad Med Sci, Guangzhou, Peoples R China

[8] Hop Cochin, AP HP, Serv Pneumol, Paris, France

[9] Fujian Canc Hosp, Dept Thorac Oncol, Fuzhou, Peoples R China

[10] Univ Malaya, Dept Med, Fac Med, Kuala Lumpur, Malaysia

[11] Univ Paul Sabatier, CHU Toulouse, Toulouse, France

[12] Pantai Hosp Kuala Lumpur, Dept Oncol, Kuala Lumpur, Malaysia

[13] Kindai Univ, Fac Med, Dept Med Oncol, Osaka, Osaka, Japan

[14] Natl Lung Hosp, Hanoi, Vietnam

[15] Tan Tock Seng Hosp, Dept Med Oncol, Singapore, Singapore

[16] IRCCS, European Inst Oncol, Div Thorac Oncol, Milan, Italy

[17] Antwerp Univ Hosp UZA, Dept Pulmonol & Thorac Oncol, Edegem, Belgium

[18] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Sichuan, Peoples R China

[19] IRCCS Humanitas Res Hosp, Milan, Italy

[20] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[21] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[22] EMD Serono, Rockland, MA USA

[23] Merck KGaA, Healthcare Business, Global Clin Dev Operat, Darmstadt, Germany

[24] Merck KGaA, Healthcare Business, Global Med Affairs, Darmstadt, Germany

[25] Merck KGaA, Healthcare Business, Global Clin Dev, Darmstadt, Germany

[26] Merck KGaA, Healthcare Business, Global Patient Safety, Darmstadt, Germany

[27] Merck KGaA, Healthcare Business, Dept Biostat, Darmstadt, Germany

[28] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PP01.84

引用

页码：E38 / E38

页数：1

共 50 条

[1] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
Kim, T. M.
Guarneri, V.
Jye, V. P.
Khaw, L. B.
Yang, J. -J.
Wislez, M.
Huang, C.
Kin, L. Chong
Mazieres, J.
Tho, L. M.
Hayashi, H.
Nhung, N.
Chia, P. L.
De Marinis, F.
Raskin, J.
Zhou, Q.
Finochhiaro, G.
Le, X.
Tan, D.
Brutlach, S.
O'Brate, A.
Adrian, S.
Berghoff, K.
Ellers-Lenz, B.
Karachaliou, N.
Wu, Y. -L.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S94 - S94
[2] Tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis
Le, Xiuning
Kim, Tae Min
Guarneri, Valentina
Voon, Pei Jye
Lim, Boon Khaw
Yang, Jinji
Wislez, Marie
Huang, Cheng
Liam, Chong Kim
Mazieres, Julien
Lye Mun Tho
Hayashi, Hidetoshi
Nguyen Nhung
Chia, Puey Ling
De Marinis, Fillippo
Raskin, Jo
Zhou, Qinghua
Finochhiaro, Giovanna
Tan, Daniel
Brutlach, Sabine
O'Brate, Aurora
Adrian, Svenja
Berghoff, Karin
Ellers-Lenz, Barbara
Karachaliou, Niki
Wu, Yi-Long
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[3] INSIGHT 2: Tepotinib plus Osimertinib in EGFR-Mutant NSCLC with Resistance to 1st-Line Osimertinib due to MET Amplification
Smit, E.
Felip, E.
Karachaliou, N.
Ellers-Lenz, B.
Wu, Y. -L.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S36 - S36
[4] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
Dooms, C.
Nadal, E.
Raskin, J.
Demedts, I.
Mazieres, J.
Wislez, M.
Abdul, S.
Mun, T. L.
Wang, C.
Viteri, S.
Le, X.
How, S. H.
Tan, D.
Takeda, M.
Veillon, R.
Karachaliou, N.
Ellers-Lenz, B.
Smit, E.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
[5] INSIGHT2: Tepotinib plus osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp
Morise, Masahiro
Sakai, Hiroshi
Kato, Terufumi
Tokito, Takaaki
Takeda, Masayuki
Tanaka, Hiroshi
Chikamori, Kenichi
Daga, Haruko
Kijima, Takashi
Ohashi, Kadoaki
Karachaliou, Niki
Ellers-Lenz, Barbara
Wu, Yi-Long
ANNALS OF ONCOLOGY, 2021, 32 : S309 - S309
[6] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
Wu, Y-L.
Dooms, C.
Nadal, E.
Raskin, J.
Demedts, I.
Mazieres, J.
Wislez, M.
Abdul Shukor, S.
Tho, L. M.
Wang, C-C.
Viteri, S.
Le, X.
How, S. H.
Tan, D.
Takeda, M.
Veillon, R.
Karachaliou, N.
Ellers-Lenz, B.
Smit, E. F. F.
ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
[7] Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib
Tan, Daniel Shao-Weng
Kim, Tae Min
Guarneri, Valentina
Voon, Pei Jye
Lim, Boon Khaw
Wislez, Marie
Huang, Cheng
Liam, Chong Kin
Mazieres, Julien
Tho, Lye Mun
Hayashi, Hidetoshi
Nhung, Nguyen
Chia, Puey Ling
De Marinis, Filippo
Le, Xiuning
Karachaliou, Niki
Brutlach, Sabine
Adrian, Svenja
Ellers-Lenz, Barbara
Wu, Yi-Long
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[8] Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Liam, C. K.
Kim, T. M.
Yang, J-J.
Huang, C.
Voon, P-J.
Tho, L. M.
Zhou, Q.
Wang, J.
Hayashi, H.
Tan, D. S. W.
Danchaivijitr, P.
Nguyen, V. N.
Wong, K. H.
Yang, J. C-H.
Le, X.
Ellers-Lenz, B.
Karachaliou, N.
Ghori, V.
Berghoff, K.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1691
[9] INSIGHT 2: Tepotinib plus osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
Smit, E. F.
Felip, E.
Karachaliou, N.
Ellers-Lenz, B.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2020, 31 : S894 - S894
[10] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT
Itchins, Malinda
Liam, Chong Kin
Ahmad, Azura
Hsia, Te-Chun
Zhou, Janying
Kim, Dong-Wan
Soo, Ross Andrew
Cheng, Ying
Lu, Shun
Shin, Sang Won
Yang, James Chih-Hsin
Zhang, Yiping
Zhao, Jun
Bruns, Rolf
Johne, Andreas
Wu, Yi-Long
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 82 - 83

← 1 2 3 4 5 →